A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

Tourette Syndrome Clinical Trial

Official title:

A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02217007
• Other study ID #: SNC-102-211 TS
• Status: Withdrawn
• Phase: Phase 2
• Start date: April 2015
• Est. completion date: February 2016

Study information

• Verified date: April 2021
• Source: Synchroneuron Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label study of SNC-102 (acamprosate calcium sustained release tablet) in adult subjects with Tourette Syndrome. Subjects will be treated with oral doses of SNC-102 800 mg on a BID basis - before breakfast and at bedtime - for 4 weeks and the same subjects will be treated with SNC-102 1600mg in the morning and 800mg in the evening for an additional 4 weeks. Subjects will be assessed for changes in tic severity, safety, and pharmacokinetics. The study hypothesis is that treatment with SNC-102 will improve the tic severity in adult subjects with Tourette Syndrome.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Diagnosis by a Board-certified neurologist or psychiatrist of Tourette Syndrome according to Diagnostic and Statistical Manual (DSM)-V criteria for Tourette's Disorder, viz.
• Both multiple motor and one or more vocal tics have been present at some time during the illness, although not necessarily concurrently.
• The tics may wax and wane in frequency but have persisted for more than 1 year since first tic onset.
• Onset is before age 18 years.
• The disturbance is not attributable to the physiological effects of a substance (e.g., cocaine) or another medical condition (e.g., Huntington's disease, postviral encephalitis).
• Moderate to severe tics as indicated by a Clinical Global Impression (CGI) score of 4 or higher on both the Screening Visit and the Baseline Visit while on their usual drug therapy for Tourette Syndrome.
• If using a permitted medication (SSRI, Serotonin-norepinephrine reuptake inhibitors (SNRI), alpha-2 agonist, benzodiazepine, dopamine antagonist, or stimulant) the dose has been stable for at least 4 weeks prior to the Screening Visit and is expected to remain stable through the conclusion of the study.
• Ability to swallow investigational tablets whole and without chewing, as demonstrated by swallowing a placebo tablet at the Screening Visit.

Exclusion Criteria:

• Diagnosis of epilepsy.
• Treatment with an antiepileptic drug with the exception of a stable dose of clonazepam. Topiramate and lamotrigine are specifically excluded.
• Unstable psychiatric status, as indicated by any change in psychotropic medication (unless approved by the Sponsor), or by psychiatric hospitalization, within 30 days prior to the Screening Visit.
• Active drug or alcohol dependence or abuse.
• Current use of cocaine, amphetamine, phencyclidine, or ketamine, documented either by history or by urinary drug screening at Screening and Baseline Visits. Drugs used to treat attention deficit-hyperactivity disorder or obsessive-compulsive symptoms are allowed if stable for at least 4 weeks prior to the Screening Visit and are expected to remain stable through the course of the trial. Any other drugs identified on drug screening will warrant exclusion only if the Principal Investigator, in consultation with the Sponsor, judges that their presence could interfere with the objectives of the trial.
• Risk of significant medication non-adherence, based on the judgment of the Principal Investigator.
• History of neuroleptic malignant syndrome.
• Significant risk, in the judgment of the Principal Investigator, of suicidal or violent behavior.
• Female subjects with a history of pre-menstrual exacerbation of tics.
• Initiation of oral contraceptive medication, insertion of progestin contraceptive implant, or change in dose, within 30 days prior to the Screening Visit, or anticipated while participating in the trial.
• History of short-bowel or other malabsorption syndrome, gastrointestinal hypermotility of any cause, or any gastrointestinal disease or surgery that, in the judgment of the Principal Investigator, could interfere with absorption of orally-administered medication, reduce intestinal transit time or pre-dispose to gastric outlet obstruction.
• Allergy or intolerance to acamprosate.
• Prior treatment with acamprosate for any indication.
• Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness.
• Use of any investigational agents within 4 weeks of Baseline.
• Pregnant or lactating female.

Related Conditions & MeSH terms

• Syndrome
• Tourette Syndrome

Intervention

Drug:
• SNC-102 sustained release tablet
SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.

Locations

Country	Name	City	State
United States	Rush University Medical Center	Chicago	Illinois
United States	North Shore University Hospital, Dept. of Psychiatry	Manhasset	New York

Sponsors (1)

Lead Sponsor	Collaborator
Synchroneuron Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in total tic severity score on the Yale Global Tic Severity Scale at 4 weeks	Determine whether SNC-102 800 mg twice daily (BID) will decrease tic severity in adult patients with Tourette Syndrome (TS), as measured by changes from baseline to 4 weeks in the total tic severity score on the Yale Global Tic Severity Scale (Y-GTSS).	4 weeks
Primary	Improvement in total tic severity score on the Yale Global Tic Severity Scale at 8 weeks	Determine whether SNC-102 1600 mg in the morning and 800 mg in the evening will decrease tic severity in adult patients with Tourette Syndrome (TS) as measured by change from baseline to Day 57 in the total tic severity score on the Yale Global Tic Severity Scale (Y-GTSS).	8 weeks
Secondary	Assess safety and tolerability	Assess the safety and tolerability of SNC-102 in the adult TS population, including assessing the effects, if any, of SNC-102 on symptoms of depression, anxiety, obsessive-compulsive disorder (OCD), and attention deficit-hyperactivity disorder (ADHD);	2, 4, 6, 8, 11 weeks
Secondary	Evaluate clinical effects of SNC-102 on tic severity at 2 weeks and 6 weeks	Further evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Y-GTSS total tic severity score at 2 weeks and 6 weeks	2, 6 weeks
Secondary	Pharmacokinetic profile of SNC-102 in Tourette Syndrome subjects	Assess the pharmacokinetics (PK) of acamprosate administered as SNC-102, including measures of the plasma concentration at 3 hours post-dose (C3h) and the trough plasma concentration (Cmin). The pharmacokinetic analysis will be based on the pre-dose and 3 hour post-dose plasma concentrations of acamprosate on the first day of dosing (Baseline) and on the Day 15, Day 29, Day 43 and Day 57 visits.	2, 4, 6, 8 weeks
Secondary	Explore relationship between study drug plasma levels and the magnitude of clinical response	Explore the relationship between steady-state acamprosate plasma levels and the magnitude of clinical response to the drug.	2, 4, 6, 8 weeks
Secondary	Evaluate clinical effects of SNC-102 on Global Clinical Impression	Evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Clinical Global Impression (CGI) at all post-baseline visits	2, 4, 6, 8, 11 weeks
Secondary	Evaluate clinical effects of SNC-102 on tic severity sub scales	Further evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Y-GTSS sub scales at all visits	2, 4, 6, 8, 11 weeks